News from CNBC Business
What is your interest today?
Bitcoin
Crypto
Btc
Ceo
Tariffs
Stocks
Investors
Crypto Assets
Shares
Stock
Cryptocurrency
Stock Market
Ethereum
Price
Markets
Xrp
Investment
Blockchain
Stablecoin
Etf
Sec
Eth
Bse
Ipo
Trade
Index
Solana
Earnings
Revenue
China
Coinbase
Inflation
Token
Wall Street
Nasdaq
Interest Rates
Sensex
Gold
Usd
Traders
Treasury
Trade War
Nse
Economy
Federal Reserve
Tesla
Profit
Bse Sensex
Digital Assets
Sp 500
Trade Relations
Wockhardt
Repo
Borana Weaves
Cpi Europe Ag
Official Trump Token
Deregulation
Corporate Holdings
Crude Oil Imports
Liquidity Protocol
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search Cnbc Business headlines…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
CNBC Business • May 21, 2025
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
Cigna’s Evernorth division reached an agreement that aims to reduce out-of-pocket expenses for employers and employees on certain weight management medications from Eli Lilly and N...
Read Full Article →
CNBC Business • May 19, 2025
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s leadership change aims to strengthen its position in the weight loss market, improve competitive standing against Eli Lilly, and address upcoming industry challenges...
Read Full Article →